Milestone Pharmaceuticals (MIST) Net Cash Flow (2018 - 2026)

Milestone Pharmaceuticals (MIST) has reported Net Cash Flow for 9 consecutive years, with $98.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 3905.53% year-over-year to $98.4 million; the trailing twelve-month figure through Jun 2026 stood at $127.2 million (up 335.16% YoY), and the FY2025 full-year result was $47.7 million, up 313.12% from the prior year.
• Net Cash Flow rose to $98.4 million in Q2 2026 per MIST's latest filing, from -$1.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $98.4 million in Q2 2026 and bottomed at -$41.4 million in Q2 2023.
• Historically, Net Cash Flow has averaged $3.1 million across 5 years, with a median of -$1.1 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Net Cash Flow tumbled 4755.88% in 2022, then jumped 3905.53% in 2026.
• Over 5 years, Net Cash Flow stood at -$29.6 million in 2022, then soared by 113.09% to $3.9 million in 2023, then soared by 222.47% to $12.5 million in 2024, then soared by 110.64% to $26.4 million in 2025, then jumped by 273.32% to $98.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $98.4 million, -$1.7 million, and $26.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.